TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Mechanical Methods of Outpatient Ripening of the Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between 39 and 41 weeks gestational age who desire elective induction of labor, based on reliable estimated gestational age (defined as ultrasonography performed before 14 weeks 0 days, or a certain last menstrual period consistent with ultrasonography performed before 21 weeks 0 days).~Exclusion Criteria:~* 1. Risk factors for placental insufficiency or intra-partum complication such as intra-uterine growth restriction, hypertensive disease, diabetes requiring insulin therapy, multiple gestation, history of previous hysterotomy, cholestasis of pregnancy, placental abnormalities including low lying placenta (\< 2 cm from cervical os), maternal cardiac disease, maternal pulmonary disease, known fetal anomaly, fetal demise, etc.~* 2. Simplified Bishop score must be \<6 and cervical dilation \<2 cm.~* 3. Women must be able to give informed consent.~* 4. Concern regarding fetal well-being, conditions which preclude vaginal birth, group B strep carriers, patients who are HIV, Hep B or Hep C positive.~* 5. Women allergic to povidone-iodine, aquacryl hydrogel or the latex-free Foley catheter.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Trans-cervical cervical balloon (Type: EXPERIMENTAL): 17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
- Hygroscopic cervical dilators (Type: EXPERIMENTAL): Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Reactivated DEFINITY or LUMASON in Patients Undergoing Rest or Stress Echocardiography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age or older at screening~* Clinically indicated stress echocardiography to take place at the UNMC echocardiography laboratory~Exclusion Criteria:~* Prior allergic reaction to Definity® or Lumason~* Pregnant women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single group, one arm study group (Type: OTHER): Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Active disease defined as:~  * Diagnosis of RA using the ACR criteria for the classification of RA for at least 6 months prior to trial entry (Screening, Visit 1)~ * Swollen joint count (SJC) ≥ 6 and tender joint count (TJC) ≥ 6 referred to as the 66/68 - joint count system~ * High sensitivity C-reactive protein (hs-CRP) ≥ 15 mg/L and/or an erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour~ * Positive rheumatoid factor (RF) ≥ 14 IU/mL and/or anti-cyclic citrullinated protein (CCP) ≥ 20 U~* An inadequate response (insufficient initial or loss of response and/or intolerance to at least one administration of these agents) to previous or current treatment with either MTX alone or MTX plus anti-tumour necrosis factor alpha (anti-TNFα) biological treatment. Subjects should not have received more than two different anti-TNFα therapies.~* Receiving MTX 15-25 mg/week (oral or parenteral) for at least 20 weeks, including the last 6 weeks prior to Baseline (Visit 3, Day 1) at a stable dose via the same route of administration and formulation. A stable dose of 12.5 mg of MTX is acceptable if the MTX dose has been reduced for reasons of toxicity, e.g. pulmonary, hepatic or haematological toxicity. MTX co-medication will be continued until the end of the trial (Week 48)~Main Exclusion Criteria:~* Primary or secondary immunodeficiency including HIV infection~* Evidence of acute or chronic infection with hepatitis B and C virus (HBV and HCV)~* Evidence (e.g. chest X-ray \[posterior-anterior view\], tuberculin/ PPD skin test, etc., according local guidelines) and/or history of active tuberculosis (TB), prior to successfully completing an anti-TB treatment. X-rays performed prior to inclusion (Screening, Visit 1) into the trial are accepted provided they were done within 3 months prior to Screening (Visit 1). Subjects with latent TB infection (LTBI) can be included~* Significant cardiac disease or history of severe COPD~* Diabetes mellitus type 1 or unstable type 2~* History of cancer within the last 5 years treated with anti-cancer chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veltuzumab 80 mg (Type: ACTIVE_COMPARATOR): None
- Veltuzumab 160 mg (Type: ACTIVE_COMPARATOR): None
- Veltuzumab 320 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of a New Complement to Physiotherapy Intervention for Positional Torticollis in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged newborn to 6 months at initial visit in physiotherapy,~* A diagnosis of PT made by a physician,~* At least 37 weeks of gestational age at delivery~Exclusion Criteria:~* Congenital muscular torticollis with fibrosis (confirmed diagnosis): because this is a rare condition that has a different rate of recovery,~* Presence of craniosynostosis (confirmed diagnosis made by a neurosurgeon),~* APGAR score of less than 7 at 5 minutes,~* Prescription of a Tubular Orthosis for Torticollis (TOT) collar or Botox intervention for the torticollis,~* Confirmed diagnosis of syndrome or neurological condition.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- 1 Booklet (Type: EXPERIMENTAL): None
- 2 standard (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥18 years old~2. Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation~Exclusion Criteria:~1. ABO incompatible with living donor~2. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
- Standard of Care (Type: NO_INTERVENTION): Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of malignant mesothelioma~  * Unresectable disease~* Must have received treatment with vatalanib on protocol CALGB-30107~PATIENT CHARACTERISTICS:~* Not specified~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Age 18 years or greater;~* Left Main CAD, defined as ≥ 50% diameter stenosis and amenable to re-vascularization by PCI;~* Willing and able to give informed consent. The patients must be able to comply with study procedures and follow-up.~* Ability to comply with minimum of 6 months of DAPT after the index procedure.~* Unprotected Left Main PCI~* Protected Left Main PCI~Exclusion criteria:~* Coexisting conditions that limit life expectancy to less than 12 months or that could affect patient's compliance with the protocol;~* Serum creatinine greater than 2.0 mg/dL;~* Cardiogenic shock;~* STEMI;~* Non-STEMI, if the cardiac troponin is not stable or starting to decline;~* Pregnancy;~* Inability to take dual antiplatelet therapy for 6 months;~* Any target lesion with previously placed stent.~* Patients disqualified for CABG surgery.~* Contraindications for OCT use:~  1. Bacteremia or sepsis~ 2. Major coagulation system abnormalities~ 3. Severe hemodynamic instability or shock~ 4. Patients diagnosed with coronary artery spasm~ 5. Acute renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optical Coherence Tomography (Type: OTHER): Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New York Blood Center National Cord Blood Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidates for bone marrow transplantation~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Umbilical cord blood unit(s) transplant (Type: EXPERIMENTAL): Transplantation of cryopreserved umbilical cord blood unit(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Point-of-care Management of Coagulopathy in Lung Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years~* Indicated for bilateral lung transplantation with diagnosis of interstitial pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, exogenous allergic alveolitis~Exclusion Criteria:~* Patients requiring plasmapheresis before lung transplantation~* Patients waiting for lung transplantation on ECMO (ECMO used as bridging to surgery)~* Patients undergoing simultaneous lung and heart transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard management of coagulopathy (Type: None): The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy.
- POC management of coagulopathy (Type: None): group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at cryopreservation ot tissue max. 38 years~* Age at transplantation 18-49 years~* At least one maintained ovary~* Premature ovarian failure~* Indication for an autologous transplantation of ovarian tissue~* Permitted pregnancy from the part of the oncologists~* Written informed consent~Exclusion Criteria:~* Age at transplantation \<18 and \>49 years~* Cryopreservation in the context of a leucaemia, neuroblastoma, Burkitt-lymphoma~Important: Inclusion is only done by one of the recruiting centers. Study participation will only be given on invitation. Please contact Principal Investigator!

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Transplantation into pelvic wall (Type: ACTIVE_COMPARATOR): Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
- Transplantation into the ovary (Type: ACTIVE_COMPARATOR): Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Planned open kidney resection, heminephrectomy, nephrectomy Signed informed consent~Exclusion Criteria:~* chronic/ongoing use of glucocorticoids (except inhalation therapy)~* ongoing use of immunosuppressive therapy~* insulin dependent diabetes~* pregnancy/breastfeeding~* allergies toward study medication, or medication in a standard treatment~* previous kidney resection on same side~* thrombectomy in vena cava above diaphragma~* surgery cannot be performed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose (Type: ACTIVE_COMPARATOR): Dexamethasone 24 mg
- Low dose (Type: ACTIVE_COMPARATOR): Dexamethasone 8 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concordance of Capillary Blood Biological Samples With Conventional Venousbiological Blood Samples.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient over the age of 18~* Affiliate or beneficiary of a social security scheme~* Express consent to participate in the study~Exclusion Criteria:~* Patient benefiting from a legal protection measure~* Patient not communicating~* Pregnant or breastfeeding woman~* Peripheral edema (taking more than 5 Kg since entering the service)~* Patient in shock (mean arterial pressure \< 65 mmHg or continuous catecholamine administration)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intensive care patients (Type: None): patient hospitalised in intensive care unit veinous and capillary ponction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Open Label Study of the Treatment of Therapy-associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium -

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patients who will undergo a percutaneous radiation therapy in the area of the small pelvis. This includes patients with following malignancies: rectal carcinoma, prostate carcinoma, endometrial carcinoma, cervix carcinoma.~* Diarrhea grade 1 and grade 2 (Classification NCI-CTCAE Version 3.0)~* ECOG-Grade 0-2~* Enlightenment and written declaration of consent to the participation.~Exclusion Criteria:~* Pregnant patients or patients in lactation period.~* Severe dysfunction of liver or kidneys~* Injury or illness of brain e.g. increased intracranial pressure, cerebral arteriosclerosis~* Epilepsy~* Hypersensitivity to components of loperamide or tincture of opium~* Ileus~* Toxic megacolon~* Pseudomembranous colitis/ antibiotic-associated colitis~* Diarrhea associated with fever and bloody stools~* Acute increase of colitis ulcerous or bacterial colitis caused by invasive pathogenes~* Severe respiratory dysfunction or severely limited lung function e.g. bronchial asthma, bronchitis~* Dysfunctional draining of biliary area, biliary colics.~* Concomitant or earlier addiction of alcohol or opiates~* Severe heart disease~* Pheochromocytoma~* Acute hepatic porphyria~* Cor pulmonale~* Morbus Addison~* Severe hypothyroidism~* Organisational problems or circumstances which prevent a complete collection of required data~* Artificial anus~* Participation in a clinical trial within the last 30 days before involvement~* Participation in an other clinical trial at the same time

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Opii normata treatment (Type: EXPERIMENTAL): Treamtment with opii normata in case of diarrhea
- Loperamid Treatment (Type: EXPERIMENTAL): Treatment with Loperamid in case of diarrhea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Removal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* ERM on clinical exam and/or macular OCT~* Visual acuity of 20/40 or worse (attributable to ERM)~Exclusion Criteria:~* Prior surgery for ERM in the study eye~* Macular edema secondary to arterial/venous occlusion(s)~* Central serous retinopathy~* Age related macular degeneration~* Diabetic cystoid macular edema~* Proliferative Diabetic Retinopathy~* Uveitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Epiretinal Membrane Surgery without ILM peel (Type: ACTIVE_COMPARATOR): None
- Epiretinal Membrane Surgery with ILM peel (ICG assisted) (Type: ACTIVE_COMPARATOR): None
- Combined CE & IOL and ERM surgery without ILM peel (Type: ACTIVE_COMPARATOR): None
- Combined CE & IOL and ERM surgery with ILM peel (ICG assisted) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility